Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
L
LUCD
vs
S&P 500
S&P 500
Over the past 12 months, LUCD has underperformed S&P 500, delivering a return of -64% compared to S&P 500's +10% growth.
Stocks Performance
LUCD vs S&P 500
Performance Gap
LUCD vs S&P 500
Performance By Year
LUCD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Lucid Diagnostics Inc
Glance View
Lucid Diagnostics makes medical tests that help doctors look for precancerous changes in the esophagus before they turn into cancer. Its main product is a screening system built around a simple cell collection device and a lab test that checks those cells for signs of Barrett’s esophagus and esophageal precancer. The company sells this as a way to find disease earlier than a standard endoscopy in people with reflux symptoms or other risk factors. The main customers are physicians, gastroenterology practices, hospitals, and health systems that order the test for patients. Lucid makes money by selling the test and related diagnostic services, either directly or through healthcare channels that bill payers for the procedure. In practice, it sits between the doctor’s office and the lab, turning a specialized screening need into a repeatable diagnostic service. What makes Lucid’s business different is that it is not a drug company or a broad medical device maker. It focuses on one narrow problem: finding esophageal precancer earlier and less invasively. That gives it a niche role in the diagnostic pathway, where adoption depends on doctors using the test and payers recognizing its value for screening and risk management.